NCT00699296View on ClinicalTrials.gov

Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

December 31, 2008

Conditions
Cutaneous T-Cell LymphomaLeukemia-Lymphoma, Adult T-Cell
Interventions
DRUG

Panobinostat (LBH589)

20mg/day p.o. on three times-a- week

Trial Locations (7)

Unknown

University Hospital of Occupational and Environmental Health, Fukuoka

Imamura Bun-in Hospital, Kagoshima

Kumamoto University Hospital, Kumamoto

University of Miyazaki Hospital, Miyazaki

Nagasaki University Hospital of Medicine and Dentistry, Nagasaki

Okayama University Hospital, Okayama

The University of Tokyo Hospital, Tokyo

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY